Our data partially support the link between Flt3ITD+ mutation and higher ROS levels [15] but also show that ROS levels were lower in most NPM1-mutated/ Flt3ITD+ cases (all CD34− AML in our cohort). The gene discussed is NPM1; the disease is acute myeloid leukemia.